Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Correspondence

Correspondence to editorial on “Adverse impact of metabolic dysfunction on fibrosis regression following direct-acting antiviral therapy: A multicenter study for chronic hepatitis C”

Tom Ryu, Young Chang, Seung Up Kim, Jae Young Jang

Clin Mol Hepatol. 2025;31(2):e203-e205. Published online February 24, 2025

DOI: https://doi.org/10.3350/cmh.2025.0179

View: 443 Download: 15 Crossref: 1

Original Article

Adverse impact of metabolic dysfunction on fibrosis regression following direct-acting antiviral therapy: A multicenter study for chronic hepatitis C

Tom Ryu, Young Chang, Soung Won Jeong, Jeong-Ju Yoo, Sae Hwan Lee, Sang Gyune Kim, Young Seok Kim, Hong Soo Kim, Seung Up Kim, Jae Young Jang

Clin Mol Hepatol. 2025;31(2):548-562. Published online January 9, 2025

DOI: https://doi.org/10.3350/cmh.2024.0904

View: 1079 Download: 99 Crossref: 1

Review

Unmet needs of chronic hepatitis C in the era of direct-acting antiviral therapy

Chung-Feng Huang, Ming-Lung Yu

Clin Mol Hepatol. 2020;26(3):251-260. Published online March 19, 2020

DOI: https://doi.org/10.3350/cmh.2020.0018

View: 16006 Download: 396 Web of Science: 44 Crossref: 46

Discussion on critical points for a tailored therapy to cure hepatitis C virus infection

Nadia Marascio, Angela Quirino, Giorgio Settimo Barreca, Luisa Galati, Chiara Costa, Vincenzo Pisani, Maria Mazzitelli, Giovanni Matera, Maria Carla Liberto, Alfredo Focà, Carlo Torti

Clin Mol Hepatol. 2019;25(1):30-36. Published online January 23, 2019

DOI: https://doi.org/10.3350/cmh.2018.0061

View: 8736 Download: 158 Web of Science: 16 Crossref: 18

Management of hepatitis C viral infection in chronic kidney disease patients on hemodialysis in the era of direct-acting antivirals

Soon Young Ko, Won Hyeok Choe

Clin Mol Hepatol. 2018;24(4):351-357. Published online March 16, 2018

DOI: https://doi.org/10.3350/cmh.2017.0063

View: 10875 Download: 354 Web of Science: 4 Crossref: 1

Management of direct antiviral agent failures

María Buti, Rafael Esteban

Clin Mol Hepatol. 2016;22(4):432-438. Published online December 25, 2016

DOI: https://doi.org/10.3350/cmh.2016.0107

View: 12267 Download: 366 Web of Science: 31 Crossref: 29

Original Article

Efficacy and safety of daclatasvir and asunaprevir for hepatitis C virus genotype 1b infection

Hee Chul Nam, Hae Lim Lee, Hyun Yang, Myeong Jun Song

Clin Mol Hepatol. 2016;22(2):259-266. Published online June 25, 2016

DOI: https://doi.org/10.3350/cmh.2016.0020

View: 10413 Download: 170 Web of Science: 8 Crossref: 7

1 |

Viewed By 10223	Epidemiology of metabolic dysfunction-associated steatotic liver disease
Viewed By 7245	MAFLD: How is it different from NAFLD?
Viewed By 5235	Global incidence and prevalence of nonalcoholic fatty liver disease
Viewed By 4721	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4672	Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment

Cited By 322	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 305	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 208	MAFLD: How is it different from NAFLD?
Cited By 104	Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis
Cited By 103	Non-alcoholic fatty liver disease: Definition and subtypes

Search